$OSG

Refiners, Not Consumers, Are Biggest Winners From Jones Act Waiver, OSG CEO Says

Overseas Shipholding Group CEO Sam Norton said the Trump emergency Jones Act waiver has benefited U.S. refiners more than consumers, citing rising 3:2:1 crack spreads from about 27% in early 2026 to ~45% in early June and 70%-75% recently. He noted foreign-flag tankers are doing domestic voyages while U.S.-flag ships stay idle. The waiver expires Aug. 16.

Original reporting
Published Jul 14, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Refiners, Not Consumers, Are Biggest Winners From Jones Act Waiver, OSG CEO Says — source image
Decision brief

The 30-second read

$OSGBearishLow
01

Why it matters

The CEO’s analysis argues the waiver has not reduced gasoline or diesel prices and instead coincided with higher refining profitability, while U.S.-flag vessels remain idle as foreign-flag ships perform domestic voyages.

02

Market read

Policy-driven shipping routing under the Jones Act waiver is positioned as a utilization and competitive issue for U.S.-flag tanker operators, with a clear Aug. 16 decision point.

03

What to watch

The article does not quantify OSG’s direct revenue or contract exposure to waiver-driven routing, and it relies on a CEO commentary rather than new company filings or guidance.

Relevance 4/10Novelty 4/10Timing: Ahead of the Aug. 16 deadline to let the emergency Jones Act waiver expire.

Background

The Trump administration invoked Section 501 of the Merchant Marine Act in March to allow approved foreign-flag vessels to carry certain petroleum products between U.S. ports, with the emergency waiver set to expire Aug. 16.

Company-level read

Ticker impact

$OSGBearishMedium confidence
Context

Overseas Shipholding Group CEO Sam Norton argues the ongoing Jones Act waiver has shifted domestic voyages to foreign-flag tankers, sidelining U.S.-flag operators.

Expected impact

Near-term sentiment risk for OSG if the waiver is extended past Aug. 16, with potential upside if it expires and U.S.-flag demand returns.

Evidence & confidence

The piece is commentary, but it cites MARAD approval activity (170 voyages as of July 13) and highlights U.S.-flag idling, which can affect utilization expectations for OSG.

Market effects

Could increase scrutiny of Jones Act waiver policy, affecting demand expectations for U.S.-flag tanker operators and potentially shifting freight economics toward foreign-flag capacity.

U.S. Gulf Coast refining and port activity may see continued domestic cargo routing by foreign-flag vessels, influencing local tanker utilization.

Iran/Strait of Hormuz risk is the stated trigger for the waiver, so any escalation or de-escalation can change waiver justification and shipping patterns.

Counterpoint

Even if refiners capture margins, the waiver may still be necessary to prevent supply disruptions; any consumer-price pass-through could lag or be offset by other market factors.

Key entities

  • Overseas Shipholding Group

    U.S.-flag tanker operator whose CEO argues the Jones Act waiver has shifted domestic voyages away from U.S.-flag vessels.

  • MARAD

    U.S. Maritime Administration, cited as continuing to approve domestic voyages under the waiver (170 approved voyages as of July 13).

  • Seafarers International Union

    Protested the continued operation of a Chinese-flagged tanker performing coastwise voyages.

  • Marathon Petroleum

    Protest location referenced, where a tanker was preparing another domestic shipment.

Related articles

$OSGMed

OCTAVE SPECIALTY GROUP INC (OSG): Results of Operations and Financial Condition

OCTAVE SPECIALTY GROUP INC (OSG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a03-0532q26ex991osgpressre.htm EX-99.1 Document Exhibit 99.1 Octave Specialty Group Reports Second Quarter 2026 Results • Insurance Distribution Segment ◦ Total revenue grew 77% to $58 million ◦ Organic revenue growth equaled 44% ◦ Ne t loss to Shareholders totaled $(4)

$UNHMed

COMMENTARY: Trump administration finds a new way to punish Medicare members — Hiking their drug bills

The article says the Trump administration, led by Medicare chief Mehmet Oz, will end the Part D Premium Stabilization Demonstration subsidy for Medicare drug coverage on Dec. 31 instead of continuing through at least 2027. It cites GAO cost estimates of about $9.8B over two years and warns premiums for 23M enrollees could rise, including possible doubling for 11M.

$CMIMed

Locally-made Cummins engine to hit market in 2027

Cummins said the EPA clarified emissions requirements, allowing its locally made X15N engine to move into market deployment. The EPA rule scales back emissions warranty requirements and removes deratement, with added lead time for useful-life rules. Cummins plans limited 2027 X15 and X10 production in Jan 2027, full production in Q4 2027 and Q3 2027. Cummins raised 2026 revenue guidance to up 10% to 13%.

$DEOMed

India warned Diageo that its whisky’s ’matured in American oak casks’ claim was misleading

Reuters reports India’s food regulator FSSAI warned Diageo’s unit United Spirits that its Royal Challenge whisky label claiming “matured in American oak casks” was misleading, saying most of the product was not matured. FSSAI also banned some Diageo and Inbrew brands for artificial flavouring. Diageo said it is engaging FSSAI and expects no financial impact.

$GEOMed

Reps. Lee, Deluzio, Dean demand overhaul at PA ICE detention facility

U.S. Reps. Madeleine Dean, Summer Lee and Chris Deluzio sent letters to GEO Group and ICE and DHS officials demanding reforms at the Moshannon Valley Processing Center, citing alleged medical staffing shortages, delayed medical screenings, and detainee deaths. They also raised concerns about ICE acting director David Venturella’s prior ties to GEO and asked for contract and compensation records within 14 days.

$GRALMed

GRAIL Announces FDA Advisory Committee Review Of Galleri Multi-Cancer Early Detection Test

GRAIL said the FDA Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for Galleri, a multi-cancer early detection blood test. The submission cites PATHFINDER 2 (25,490 participants, one year) and NHS-Galleri (over 70,000). GRAIL says Galleri detects methylation patterns, with low false positives and accurate signal origin prediction.